Kim Felix J
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
Sidney Kimmel Cancer Center, Philadelphia, PA, USA.
Handb Exp Pharmacol. 2017;244:1-11. doi: 10.1007/164_2017_41.
For over 40 years, scientists have endeavored to understand the so-called sigma receptors. During this time, the concept of sigma receptors has continuously and significantly evolved. With thousands of publications on the subject, these proteins have been implicated in various diseases, disorders, and physiological processes. Nevertheless, we are just beginning to understand what sigma proteins do and how they work. Two subtypes have been identified, Sigma1 and Sigma2. Whereas Sigma1 (also known as sigma-1 receptor, Sig1R, σ1 receptor, and several other names) was cloned over 20 years ago, Sigma2 (sigma-2 receptor, σ2 receptor) was cloned very recently and had remained a pharmacologically defined entity. In this volume, we will focus primarily on Sigma1. We will highlight several key subject areas in which Sigma1 has been well characterized as well as (re)emerging areas of interest. Despite the large number of publications regarding Sigma1, several fundamental questions remain unanswered or only partially answered. Most of what we know about Sigma1 comes from pharmacological studies; however, a clearly defined molecular mechanism of action remains elusive. One concept has become clear; Sigma1 is not a traditional receptor. Sigma1 is now considered a unique pharmacologically regulated integral membrane chaperone or scaffolding protein. A number of landmark discoveries over the past decade have begun to reshape the concept of sigma receptors. With the rapid emergence of new information, development of new tools, and changing conceptual frameworks, the field is poised for a period of accelerated progress.
四十多年来,科学家们一直致力于了解所谓的西格玛受体。在此期间,西格玛受体的概念不断且显著地演变。关于这个主题已有数千篇出版物,这些蛋白质与各种疾病、病症和生理过程有关。然而,我们才刚刚开始了解西格玛蛋白的作用及工作方式。已确定了两种亚型,西格玛1和西格玛2。西格玛1(也称为西格玛-1受体、Sig1R、σ1受体以及其他几个名称)在二十多年前就已被克隆,而西格玛2(西格玛-2受体、σ2受体)直到最近才被克隆,此前一直是一个药理学定义的实体。在本卷中,我们将主要关注西格玛1。我们将突出几个西格玛1已得到充分表征的关键主题领域以及(重新)出现的感兴趣领域。尽管关于西格玛1的出版物数量众多,但仍有几个基本问题未得到解答或仅得到部分解答。我们对西格玛1的了解大多来自药理学研究;然而,其明确的分子作用机制仍然难以捉摸。一个概念已经明确;西格玛1不是传统的受体。西格玛1现在被认为是一种独特的药理学调节的整合膜伴侣或支架蛋白。过去十年中的一些具有里程碑意义的发现已开始重塑西格玛受体的概念。随着新信息的迅速涌现、新工具的开发以及概念框架的变化,该领域正处于加速发展的时期。